We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

In The Midnight Hour: FDA Issues 2 Draft Guidances and a First Amendment Memorandum on the Cusp of a New Administration

20 January 2017

Pharmaceutical and Biotechnology Alert

Over the past few days, FDA issued three documents related to the scope of permissible communications by drug and device companies to various parties. We believe FDA aimed to accomplish two things through these documents. First, it defines more broadly acceptable claims and evidentiary support for certain forms of promotion and effectively narrows the scope of its past enforcement positions. Second, the Agency simultaneously asserts that strong public health and policy reasons support its long-held position that promotion of an unapproved use of an approved product should remain prohibited.

Click here to read summaries of the three documents and our initial analysis of them.


Loading data